JOYAJOY – The World’s 1st GAMIFIED Social Media
JOYAJOY – The World’s 1st GAMIFIED Social Media
05 sept. 2024 10h49 HE | JOYAJOY
JOYAJOY, the World’s 1st GAMIFIED Social Media, cultivates a Joyful Place for Influencers and Followers to share joy without worrying about cyberbullying.
Nick Laws and David Cash of Catalyst by Cash Labs
Cash Labs Joins Forces with Nick Laws to Launch Catalyst, a Transformative Talent Development Division
30 août 2024 07h11 HE | Cash Labs
Cash Labs partners with Nick Laws to launch Catalyst, a new talent division empowering digital innovators with a human-first approach to talent management.
Full Logo - OKYO .jpg
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
08 avr. 2024 19h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
Logo 1-1.png
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
02 avr. 2024 07h00 HE | Chemomab Therapeutics
Chemomab's KOL primary sclerosing cholangitis virtual event on April 10 at 10:00 AM ET will include physician & patient PSC experts & a live Q&A session.
Full Logo - OKYO .jpg
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
22 mars 2024 07h00 HE | OKYO Pharma LTD
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief
Full Logo - OKYO .jpg
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
21 mars 2024 07h00 HE | OKYO Pharma LTD
-Phase 2 OK-101 efficacy data to be released March 22nd, 2024- -KOL Event to be held on April 9th, 2024 at 12 PM ET- LONDON and NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited...
Full Logo - OKYO .jpg
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
20 mars 2024 07h00 HE | OKYO Pharma LTD
LONDON and NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of...
logo.jpg
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023
02 nov. 2023 07h00 HE | AC Immune SA
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune...
STRATA Skin Sciences Logo.jpg
STRATA Skin Sciences to Host Virtual KOL Event on XTRAC® and TheraClear®X
24 août 2023 08h00 HE | STRATA Skin Sciences, Inc.
HORSHAM, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for...
Elevar Logo for Common Use.png
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
03 août 2023 09h00 HE | Elevar Therapeutics
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...